Skip to main content

Advertisement

SpringerLink
Log in

Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis

  • ORIGINAL PAPER
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

An Erratum to this article was published on 01 July 2007

Summary

A recent meta–analysis of the Cholesterol Treatment Trialists’ (CTT) Collaboration comes to the clear conclusion that a reduction in LDL–C using statins of 1 mmol/l (39 mg/dl) leads to a decrease in overall mortality by 12%, in coronary mortality by 19% and in the incidence of strokes by 17%, independent of the LDL–C level prior to the start of treatment. We conducted a systematic review retrieving 18 studies with a total of 97 861 participants. Differences in average LDL–C reductions between the intervention and control groups during the follow–up and relative risks according to different clinical endpoints were extracted from the original publications. Metaregression analyses showed that reduction in LDL–C accounted for more than 75% of the variance in risk reductions for overall mortality and cardiovascular endpoints. On the basis of our estimates, a reduction in LDL–C of 1 mmol/l (39 mg/dl) leads to reductions in overall mortality, coronary mortality, incidence of non–fatal myocardial infarction, the combination of coronary mortality and non–fatal myocardial infarction, stroke and any vascular event by 15% (95% CI: 11–20%), 24% (95% CI: 20–28%), 27% (95% CI: 20–32%), 25% (95% CI: 22–29%), 24% (18–29%) and 22% (95% CI: 19–26%), respectively. We conclude that the extent to which statins lower LDL–C is strongly related to the improvement of clinical outcomes achieved by this class of drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anonymus (2005) Benefit evaluation of statins with special consideration of atorvastatin. Version 1.0 as released on August 15, 2005. Institute for Quality Assurance and Cost–Effectiveness in Healthcare. http://www.iqwig.de

  2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol–lowering treatment: prospective meta–analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366:1267– 1278

    Article  PubMed  CAS  Google Scholar 

  3. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504

    Article  PubMed  CAS  Google Scholar 

  4. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton–Menys V, Fuller JH (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo–controlled trial. Lancet 364:685–696

    Article  PubMed  CAS  Google Scholar 

  5. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292:1307– 1316

    Article  PubMed  CAS  Google Scholar 

  6. Downs J, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622

    Article  PubMed  CAS  Google Scholar 

  7. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico) (2000) Results of the low–dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 1:810–820

    Google Scholar 

  8. Gould LA, Rossouw JE, Santanello NC, Heyse JF, Furberg CD (1998) Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97:946–952

    PubMed  CAS  Google Scholar 

  9. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227–239

    Article  PubMed  Google Scholar 

  10. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen–Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo–controlled trial. Lancet 361:2024–2031

    Article  PubMed  CAS  Google Scholar 

  11. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435

    Article  PubMed  CAS  Google Scholar 

  12. LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta–analysis of randomized controlled trials. JAMA 282: 2340–2346

    Article  PubMed  CAS  Google Scholar 

  13. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and metaanalysis. BMJ 326:1423

    Article  PubMed  CAS  Google Scholar 

  14. Law MR, Wald NJ, Thompson SG (1994) By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease. BMJ 308:367–373

    PubMed  CAS  Google Scholar 

  15. MRC/BHF Heart Protection Study Group (2002) MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20 536 high–risk individuals: a randomised placebocontrolled trial. Lancet 360:7–22

    Article  Google Scholar 

  16. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J (2005) High–dose atorvastatin vs usual–dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437–2445

    Article  PubMed  CAS  Google Scholar 

  17. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97:1453–1460

    PubMed  CAS  Google Scholar 

  18. Sacks F, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E (1998) Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 97:1446–1452

    PubMed  CAS  Google Scholar 

  19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335:1001–1009

    Article  PubMed  CAS  Google Scholar 

  20. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389

    Google Scholar 

  21. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285:1711–1718

    Article  PubMed  CAS  Google Scholar 

  22. Serruys PW, De Feyter PJ, Benghozi R, Hugenholtz PG, Lesaffre E (2001) The Lescol Intervention Prevention Study (LIPS): a double–blind, placebo–controlled, randomized trial of the longterm effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. Int J Cardiovasc Intervent 4:165–172

    Article  PubMed  Google Scholar 

  23. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lowerthan– average cholesterol concentrations, in the Anglo–Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT–LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158

    Article  PubMed  CAS  Google Scholar 

  24. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630

    Article  PubMed  CAS  Google Scholar 

  25. Simes R, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators (2002) Relationship between lipid levels and clinical outcomes in the Long–term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on–study lipid levels? Circulation 105:1162–1169

    Article  PubMed  CAS  Google Scholar 

  26. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD (2000) Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long–term coronary, cardiovascular, and all–cause mortality and to longevity. JAMA 284:311–318

    Article  PubMed  CAS  Google Scholar 

  27. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial (ALLHAT–LLT). JAMA 288: 2998–3007

    Article  Google Scholar 

  28. The Long–Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–1357

    Article  Google Scholar 

  29. The Post Coronary Artery Bypass Graft Trial Investigators (1997) The effect of aggressive lowering of lowdensity lipoprotein cholesterol levels and low–dose anticoagulation on obstructive changes in saphenous–vein coronary–artery bypass grafts. N Engl J Med 336:153–162

    Article  Google Scholar 

  30. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238– 248

    Article  PubMed  CAS  Google Scholar 

  31. West of Scotland Coronary Prevention Study Group (1998) Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440–1445

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Synlab Center of Laboratory Diagnostics Heidelberg, 104780, 69037, Heidelberg, Germany

    Winfried März MD

  2. BGStats Consulting, Hochstrasse 7, 8071, Graz, Austria

    Bernd Genser

Authors
  1. Bernd Genser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Winfried März MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Winfried März MD.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s00392-007-0552-6.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Genser, B., März, W. Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis. Clin Res Cardiol 95, 393–404 (2006). https://doi.org/10.1007/s00392-006-0403-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-006-0403-x

Key words

Search

Navigation